Gephyrin: where do we stand, where do we go?

被引:237
|
作者
Fritschy, Jean-Marc [1 ]
Harvey, Robert J. [2 ]
Schwarz, Guenter [3 ]
机构
[1] Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland
[2] Sch Pharm, Dept Pharmacol, London WC1N 1AX, England
[3] Univ Cologne, Inst Biochem, D-50674 Cologne, Germany
基金
英国医学研究理事会;
关键词
D O I
10.1016/j.tins.2008.02.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gephyrin is a multifunctional protein responsible for molybdenum cofactor synthesis and the clustering of glycine and GABA(A) receptors at inhibitory synapses. Based on the structure of its two conserved domains, G and E, gephyrin is thought to form a hexagonal lattice serving as a scaffold for accessory proteins at postsynaptic sites. However, important aspects of gephyrin gene expression, protein structure and regulation, as well as the role of gephyrin in synapse formation and plasticity, remain poorly understood. Here we review the current state of knowledge about gephyrin, highlighting new research avenues based on a different structural model and a revised nomenclature for gephyrin splice variants. Unraveling the biology of gephyrin will further our understanding of glycinergic and GABAergic synapses in health and disease.
引用
收藏
页码:257 / 264
页数:8
相关论文
共 50 条
  • [1] ColVI myopathies: where do we stand, where do we go?
    Valérie Allamand
    Laura Briñas
    Pascale Richard
    Tanya Stojkovic
    Susana Quijano-Roy
    Gisèle Bonne
    [J]. Skeletal Muscle, 1
  • [2] ColVI myopathies: where do we stand, where do we go?
    Allamand, Valerie
    Brinas, Laura
    Richard, Pascale
    Stojkovic, Tanya
    Quijano-Roy, Susana
    Bonne, Gisele
    [J]. SKELETAL MUSCLE, 2011, 1
  • [3] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    [J]. TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [4] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    [J]. EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [5] Treatment of negative symptoms: Where do we stand, and where do we go?
    Aleman, Andre
    Lincoln, Tania M.
    Bruggeman, Richard
    Melle, Ingrid
    Arends, Johan
    Arango, Celso
    Knegtering, Henderikus
    [J]. SCHIZOPHRENIA RESEARCH, 2017, 186 : 55 - 62
  • [6] Where do we stand on neuroprotection? Where do we go from here?
    Shoulson, I
    [J]. MOVEMENT DISORDERS, 1998, 13 : 46 - 48
  • [7] THE CYTOGENETICS OF RENAL TUMORS - WHERE DO WE STAND, WHERE DO WE GO
    WALTER, TA
    BERGER, CS
    SANDBERG, AA
    [J]. CANCER GENETICS AND CYTOGENETICS, 1989, 43 (01) : 15 - 34
  • [8] RED ALGAL SPECIES: WHERE DO WE STAND, WHERE DO WE GO?
    Zuccarello, G. C.
    [J]. PHYCOLOGIA, 2013, 52 (04) : 127 - 128
  • [9] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    [J]. CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142
  • [10] THE DECADE OF TOTAL QUALITY - WHERE DO WE STAND - WHERE DO WE GO
    YEAGER, R
    [J]. PIMA MAGAZINE, 1994, 76 (03): : S2 - S3